AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30512084 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary cervical HPV testing
Number of subjects: 0
Study 30512084 — intervention group
Group type: COMPARATOR
Intervention: Cytology testing
Number of subjects: 0
Study 26568203 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 sets of 8 repetitions with 3 min of rest between sets (8S)
Number of subjects: 17
Study 26568203 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 sets of 4 repetitions with 80 s of rest between sets (4S)
Number of subjects: 17
Study 26568203 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 sets of 1 repetition with 18.5 s of rest between each repetition (1S)
Number of subjects: 17
Study 26568203 — intervention group
Group type: COMPARATOR
Intervention: Control session (not specified)
Number of subjects: 17
Study 25270857 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (0.5 μg/kg bolus over 60 s followed by 0.05 μg/kg/min continuous infusion for 20 min)
Number of subjects: 0
Study 25270857 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.9% sodium chloride infusion at a volume and rate equal to that of remifentanil)
Number of subjects: 0
Study 25270857 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 0
Study 25270857 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0
Study 22357846 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 27
Study 22357846 — intervention group
Group type: COMPARATOR
Intervention: Atomoxetine
Number of subjects: 27
Study 22357846 — intervention group
Group type: COMPARATOR
Intervention: Citalopram
Number of subjects: 27
Study 20585896 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed message (describing benefits of receiving the vaccine)
Number of subjects: 72
Study 20585896 — intervention group
Group type: COMPARATOR
Intervention: Loss-framed message (describing costs of not receiving the vaccine)
Number of subjects: 72
Study 16930145 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis with a single dose of amoxicillin and clavulanic acid (group A, n = 193)
Number of subjects: 386
Study 16930145 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group B, n = 193)
Number of subjects: 386
Study 15848701 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab induction (30 mg IV intraoperatively) with rapid corticosteroid elimination
Number of subjects: 32
Study 15848701 — intervention group
Group type: COMPARATOR
Intervention: Control group with alternate day rabbit antithymocyte globulin (rATG) induction with a steroid-based regimen
Number of subjects: 32
Study 15848701 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab induction
Number of subjects: 32
Study 15848701 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 15848701 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 32
Study 15848701 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab group
Number of subjects: 32
Study 12486437 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide (0.015 or 0.03 microg/kg/min)
Number of subjects: 255
Study 12486437 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine (>=5 microg/kg/min)
Number of subjects: 255
Study 10354696 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation (R)
Number of subjects: 21
Study 10354696 — intervention group
Group type: COMPARATOR
Intervention: Oxygen therapy (T)
Number of subjects: 21
Study 8073235 — intervention group
Group type: EXPERIMENTAL
Intervention: Insurance supplement for unconventional medicine (experimental group)
Number of subjects: 5000
Study 8073235 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected insurance supplement for unconventional medicine (third group)
Number of subjects: 5000
Study 8073235 — intervention group
Group type: COMPARATOR
Intervention: No coverage of unconventional medicine (control group)
Number of subjects: 5000
Study 2645662 — intervention group
Group type: EXPERIMENTAL
Intervention: Top-up transfusions to keep haemoglobin concentrations above 10 g/dl
Number of subjects: 20
Study 2645662 — intervention group
Group type: COMPARATOR
Intervention: No transfusions, allowing haemoglobin concentrations to fall below 10 g/dl
Number of subjects: 20
Study 29768301 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with bevacizumab (457 patients, 128 achieved pCR)
Number of subjects: 920
Study 29768301 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy without bevacizumab
Number of subjects: 920
Study 25482371 — intervention group
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine (NAC) 1800mg day(-1)
Number of subjects: 60
Study 25482371 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (MET) 1500mg day(-1)
Number of subjects: 60
Study 25482371 — intervention group
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine (NAC) 1800mg day(-1) + Metformin (MET) 1500mg day(-1)
Number of subjects: 60
Study 24081186 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (25 IU/day for 60 days)
Number of subjects: 65
Study 21695594 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Survey Short Form (SF‐36)
Number of subjects: 3622
Study 21695594 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-week Morbidity Rate
Number of subjects: 3622
Study 21695594 — intervention group
Group type: EXPERIMENTAL
Intervention: Job Satisfaction
Number of subjects: 3622
Study 21695594 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple stepwise linear regression analysis
Number of subjects: 3622
Study 21695594 — intervention group
Group type: EXPERIMENTAL
Intervention: Digestive system disease
Number of subjects: 3622
Study 21695594 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary system disease
Number of subjects: 3622
Study 21695594 — intervention group
Group type: EXPERIMENTAL
Intervention: Gynecological disease
Number of subjects: 3622
Study 19590244 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein
Number of subjects: 20
Study 19590244 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 20
Study 17900691 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser peripheral iridotomy (LPI) in one eye
Number of subjects: 205
Study 15799724 — intervention group
Group type: EXPERIMENTAL
Intervention: Transpupillary thermotherapy (TTT)
Number of subjects: 28
Study 15799724 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 28
Study 12772546 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes self-management program
Number of subjects: 109
Study 12772546 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention (control group)
Number of subjects: 109
Study 12772546 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants recruited from FBOs
Number of subjects: 109
Study 12772546 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants recruited from health system
Number of subjects: 109
Study 12772546 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants recruited from community
Number of subjects: 109
Study 12772546 — intervention group
Group type: COMPARATOR
Intervention: Participants recruited from FBOs (control)
Number of subjects: 109
Study 12772546 — intervention group
Group type: COMPARATOR
Intervention: Participants recruited from health system (control)
Number of subjects: 109
Study 12772546 — intervention group
Group type: COMPARATOR
Intervention: Participants recruited from community (control)
Number of subjects: 109
Study 9275269 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate specific antigen prescreening followed by digital rectal examination, transrectal ultrasound, and biopsy if indicated.
Number of subjects: 1000
Study 9275269 — intervention group
Group type: COMPARATOR
Intervention: Prostate specific antigen prescreening only (no additional screening).
Number of subjects: 1000
Study 9275269 — intervention group
Group type: EXPERIMENTAL
Intervention: Information materials and invitation procedures.
Number of subjects: 1000
Study 9275269 — intervention group
Group type: COMPARATOR
Intervention: Single prostate specific antigen determination.
Number of subjects: 1000
Study 1773136 — intervention group
Group type: EXPERIMENTAL
Intervention: AHBuBP (5 mg/day on two consecutive days every 3 months for one year)
Number of subjects: 40
Study 1773136 — intervention group
Group type: COMPARATOR
Intervention: Calcium (oral)
Number of subjects: 40
Study 1773136 — intervention group
Group type: EXPERIMENTAL
Intervention: AHBuBP
Number of subjects: 40
Study 7265072 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen replacement
Number of subjects: 145
Study 7265072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 31095119 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpharmacologic interventions for chronic low back pain
Number of subjects: 10
Study 31095119 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 10
Study 29259055 — intervention group
Group type: EXPERIMENTAL
Intervention: Hughes repair
Number of subjects: 30
Study 29259055 — intervention group
Group type: COMPARATOR
Intervention: Standard mass closure
Number of subjects: 30
Study 26341174 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g tranexamic acid
Number of subjects: 200
Study 26341174 — intervention group
Group type: COMPARATOR
Intervention: 5% glucose (placebo)
Number of subjects: 200
Study 24355417 — intervention group
Group type: EXPERIMENTAL
Intervention: Resourcefulness training (RT), a cognitive-behavioral intervention, delivered over a 6 week study period.
Number of subjects: 0
Study 21919984 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate administration
Number of subjects: 0
Study 21919984 — intervention group
Group type: COMPARATOR
Intervention: Control group (no methotrexate)
Number of subjects: 0
Study 19685729 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment of scalp-acupuncture, body-acupuncture, and abdominal-acupuncture
Number of subjects: 222
Study 19685729 — intervention group
Group type: COMPARATOR
Intervention: Body-acupuncture only (control group)
Number of subjects: 222
Study 17616785 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-choline diet for up to 42 days or until organ dysfunction developed
Number of subjects: 33
Study 17616785 — intervention group
Group type: COMPARATOR
Intervention: Baseline diet containing the recommended adequate intake of choline
Number of subjects: 33
Study 15337874 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (150 mg daily)
Number of subjects: 41
Study 15337874 — intervention group
Group type: COMPARATOR
Intervention: Heparin administration
Number of subjects: 41
Study 11435050 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheal intubation
Number of subjects: 40
Study 11435050 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA) insertion
Number of subjects: 40
Study 31262398 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone sustained-release tablets (TSR)
Number of subjects: 0
Study 31262398 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone immediate-release formulation (TIR)
Number of subjects: 0
Study 31262398 — intervention group
Group type: COMPARATOR
Intervention: Food conditions
Number of subjects: 0
Study 31262398 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple dosage of TSR and TIR
Number of subjects: 0
Study 7797125 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (50 micrograms, subcutaneously, three times daily)
Number of subjects: 12
Study 7797125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2152036 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia (TIVA) with propofol (group P)
Number of subjects: 40
Study 2152036 — intervention group
Group type: COMPARATOR
Intervention: Balanced‐anaesthesia with sodium thiopental + isoflurane + N2O (group M)
Number of subjects: 40
Study 383719 — intervention group
Group type: EXPERIMENTAL
Intervention: AO‐plate fixation
Number of subjects: 100
Study 383719 — intervention group
Group type: COMPARATOR
Intervention: Conservative methods
Number of subjects: 100
Study 31671801 — intervention group
Group type: EXPERIMENTAL
Intervention: Grey Wolf Optimization (GWO) with Multi-Layer Perceptron (MLP)
Number of subjects: 0
Study 31671801 — intervention group
Group type: EXPERIMENTAL
Intervention: Biogeography-Based Optimization (BBO) with Multi-Layer Perceptron (MLP)
Number of subjects: 0
Study 31671801 — intervention group
Group type: EXPERIMENTAL
Intervention: BBO-based ensemble
Number of subjects: 0
Study 28251726 — intervention group
Group type: EXPERIMENTAL
Intervention: CSII
Number of subjects: 24
Study 28251726 — intervention group
Group type: COMPARATOR
Intervention: MDI
Number of subjects: 24
Study 25814050 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate 5-10 mg daily
Number of subjects: 23
Study 25814050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 25814050 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate (open label phase)
Number of subjects: 23
Study 22823583 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral electroacupuncture at Sanyinjiao (SP6) for Cold and Dampness Stagnation pattern
Number of subjects: 501
Study 22823583 — intervention group
Group type: COMPARATOR
Intervention: Bilateral electroacupuncture at Xuanzhong (GB39) for Cold and Dampness Stagnation pattern
Number of subjects: 501
Study 22823583 — intervention group
Group type: COMPARATOR
Intervention: Bilateral electroacupuncture at nonacupoint for Cold and Dampness Stagnation pattern
Number of subjects: 501
Study 22823583 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral electroacupuncture at Sanyinjiao (SP6) for Qi and Blood Stagnation pattern
Number of subjects: 501
Study 22823583 — intervention group
Group type: COMPARATOR
Intervention: Bilateral electroacupuncture at Xuanzhong (GB39) for Qi and Blood Stagnation pattern
Number of subjects: 501
Study 22823583 — intervention group
Group type: COMPARATOR
Intervention: Bilateral electroacupuncture at nonacupoint for Qi and Blood Stagnation pattern
Number of subjects: 501
Study 22823583 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral electroacupuncture at Sanyinjiao (SP6) for Qi and Blood Deficiency pattern
Number of subjects: 501
Study 22823583 — intervention group
Group type: COMPARATOR
Intervention: Bilateral electroacupuncture at Xuanzhong (GB39) for Qi and Blood Deficiency pattern
Number of subjects: 501
Study 22823583 — intervention group
Group type: COMPARATOR
Intervention: Bilateral electroacupuncture at nonacupoint for Qi and Blood Deficiency pattern
Number of subjects: 501
Study 21097688 — intervention group
Group type: EXPERIMENTAL
Intervention: Revalor‐X (200 mg of TBA and 40 mg of E(2))
Number of subjects: 10
Study 21097688 — intervention group
Group type: EXPERIMENTAL
Intervention: Revalor‐IS/S (200 mg of TBA and 40 mg of E(2); reimplanted at 68 to 74 d)
Number of subjects: 10
Study 21097688 — intervention group
Group type: COMPARATOR
Intervention: Revalor‐S (120 mg of TBA and 24 mg of E(2))
Number of subjects: 10
Study 21097688 — intervention group
Group type: EXPERIMENTAL
Intervention: Revalor‐IS/S (reimplanted at 44 to 47 d)
Number of subjects: 10
Study 21097688 — intervention group
Group type: EXPERIMENTAL
Intervention: Revalor‐X
Number of subjects: 10
Study 21097688 — intervention group
Group type: EXPERIMENTAL
Intervention: Revalor‐IS/S (reimplanted at 90 to 103 d)
Number of subjects: 10
Study 19863709 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive lecture
Number of subjects: 157
Study 19863709 — intervention group
Group type: COMPARATOR
Intervention: Computerised tutorial
Number of subjects: 157
Study 17443749 — intervention group
Group type: COMPARATOR
Intervention: Hydrotherapy classes
Number of subjects: 152
Study 17443749 — intervention group
Group type: COMPARATOR
Intervention: Tai Chi classes
Number of subjects: 152
Study 15291654 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (high frequency over left DLPFC)
Number of subjects: 41
Study 15291654 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (combined high- and low-frequency to left and right DLPFC)
Number of subjects: 41
Study 15291654 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 41
Study 11440285 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/d
Number of subjects: 240
Study 11440285 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg/d
Number of subjects: 240
Study 9931911 — intervention group
Group type: EXPERIMENTAL
Intervention: HAI 5-FU/FA
Number of subjects: 0
Study 9931911 — intervention group
Group type: EXPERIMENTAL
Intervention: HAI FUDR
Number of subjects: 0
Study 9931911 — intervention group
Group type: COMPARATOR
Intervention: i.v. 5-FU/FA
Number of subjects: 0
Study 9848303 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous endometrial coculture
Number of subjects: 42
Study 9848303 — intervention group
Group type: COMPARATOR
Intervention: Conventional medium
Number of subjects: 42
Study 2784007 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation of locus coeruleus (LC) with chronic unilateral electrodes; stimulation involved a 6-min stimulus with discontinuous bursts of pulses.
Number of subjects: 3
Study 2784007 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation of locus coeruleus (LC) for epilepsy management.
Number of subjects: 3
Study 334472 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (300 mg/day)
Number of subjects: 24
Study 334472 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (2.1 g/day)
Number of subjects: 24
Study 334472 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylbutazone (600 mg/day)
Number of subjects: 24
Study 334472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 28820857 — intervention group
Group type: EXPERIMENTAL
Intervention: DJ40
Number of subjects: 11
Study 28820857 — intervention group
Group type: EXPERIMENTAL
Intervention: DJ40 and DJ60
Number of subjects: 11
Study 28820857 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-second jump test
Number of subjects: 11
Study 29199544 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth-based weight loss program with video conference health coaching support
Number of subjects: 25
Study 29199544 — intervention group
Group type: COMPARATOR
Intervention: Control group (no active intervention)
Number of subjects: 25
Study 28608601 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture treatment for 8 weeks
Number of subjects: 196
Study 25859828 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal sonography (5‐9 MHz) for detecting anal sphincter injuries
Number of subjects: 201
Study 23727631 — intervention group
Group type: EXPERIMENTAL
Intervention: Tart cherry juice
Number of subjects: 58
Study 23727631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 21663885 — intervention group
Group type: EXPERIMENTAL
Intervention: Care guided by hand‐carried echocardiography
Number of subjects: 453
Study 21663885 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 453
Study 21663885 — intervention group
Group type: EXPERIMENTAL
Intervention: Care guided by hand‐carried echocardiography (subgroup analysis)
Number of subjects: 453
Study 21663885 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand‐carried echocardiography
Number of subjects: 453
Study 19638111 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope laryngoscope
Number of subjects: 60
Study 19638111 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 60
Study 19638111 — intervention group
Group type: COMPARATOR
Intervention: Both GlideScope and Macintosh laryngoscopes
Number of subjects: 60
Study 16682420 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV prevention course promoting condom use
Number of subjects: 10954
Study 16682420 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV prevention course promoting condom use with emergency contraception
Number of subjects: 10954
Study 16682420 — intervention group
Group type: COMPARATOR
Intervention: Existing sex education course
Number of subjects: 10954
Study 14699368 — intervention group
Group type: EXPERIMENTAL
Intervention: Localized high-dose UVA1 irradiation
Number of subjects: 27
Study 14699368 — intervention group
Group type: COMPARATOR
Intervention: Topical cream psoralen-UVA (PUVA)
Number of subjects: 27
Study 11726262 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB (3g.day(‐1))
Number of subjects: 8
Study 11726262 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine (LEU, 3g.day(‐1))
Number of subjects: 8
Study 11726262 — intervention group
Group type: COMPARATOR
Intervention: Placebo (CON, 3g.day(‐1))
Number of subjects: 8
Study 9163613 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (40 mg/d)
Number of subjects: 112
Study 9163613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 8203796 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide nasal spray
Number of subjects: 100
Study 8203796 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate nasal spray
Number of subjects: 100
Study 3280157 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (2 g bid, orally)
Number of subjects: 20
Study 3280157 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (3 g as a bolus followed by an infusion of 2 mg/kg/min for 30 min, intravenously)
Number of subjects: 20
Study 3280157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30772754 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Immunoglobulin (IVIG)
Number of subjects: 39
Study 30772754 — intervention group
Group type: COMPARATOR
Intervention: Placebo (albumin)
Number of subjects: 39
Study 27702556 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent hypoxia (IH) plus body weight‐supported treadmill training (BWSTT)
Number of subjects: 35
Study 27702556 — intervention group
Group type: COMPARATOR
Intervention: Continued normoxia (placebo) plus body weight‐supported treadmill training (BWSTT)
Number of subjects: 35
Study 25262459 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean lifestyle intervention (educational program on nutrition and monitored physical activity)
Number of subjects: 260
Study 25262459 — intervention group
Group type: COMPARATOR
Intervention: Conventional follow-up (control group)
Number of subjects: 260
Study 25262459 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean lifestyle intervention
Number of subjects: 260
Study 23808255 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine solution intravenous use
Number of subjects: 40